Downloading...
Download

VRAY

#VRA/USDT#VRA We have a bearish channel pattern on a 12-hour frame, the price moves within it, adheres to its limits well, and is expected to break it upwards strongly. We have a support area at the lower border of the channel at a price of 0.00500 We have a tendency to stabilize above moving average 100 We have a downtrend on the RSI indicator that is about to break higher, supporting the price higher Entry price is 0.00600 The first target is 0.00800 The second goal is 0.00950 The third goal is 0.01150
Long
by CryptoAnalystSignal
2
VRAY ViewRay Oversold | Calls to BuyVRAY ViewRay went down due to market conditions on no particular news. In fact, in a report released on Feb 28, Oppenheimer reiterated a Buy rating on VRAY Viewray, with a price target of $8.00. The stock is now trading at $3.36, being extremely oversold, with the RSI at $16.92. Looking at the options chain, I would buy the $4 strike price Calls with 2023-4-21 expiration date for about $0.10 premium. Looking forward to read your opinion about it.
VLong
by TopgOptions
VRAY about to turn bullishVRAY has been on a downtrend this whole year however there has been significant buying activity lately. The weekly MACD is about to turn bullish while the RSI has just had a higher low and is trying to come out of oversold territory. Currently VRAY is close to its 52 week low price. There has been large buying activity from the insiders, CEO, CSO (chief scientific officer)as well as institutions. This can be seen here money.cnn.com Their net revenue has almost doubled every year from 2015 to 2018 and the EPS (Earnings per share) is increasing steadily. The health industry is an ever growing industry and Viewray provides cutting edge MRI technology. The earnings are coming up on November 13. Expecting the price to go up in the coming months. *Note: This is not financial advise. Please do your own research.
VLong
by CryptoPaily
VRAY - Monster Drop. Can It Retrace The Losses?ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH. P/E Current -4.03 P/E Ratio (with extraordinary items) -3.37 SHORT INTEREST 22.51M 07/31/19 Average Recommendation: BUY Average Target Price: 6.80
VLong
by DEXWireNews